Lipitor Patents Upheld by Federal Trial Judge
December 16, 2005 A federal judge Friday upheld the validity of two key U.S. patents on Pfizer Inc.’s (PFE) Lipitor [...]
Lipitor Summary: Ranbaxy likely to prevail
February 4, 2005 In order for Ranbaxy to prevail at trial, the judge: Must interpret the ’883 patent as limited [...]
Lipitor Trial Day 1: Pfizer v. Ranbaxy
December 1, 2004 Oct. 30, 2003–Merck & Co., Inc. announced today that the U.S. Court of Appeals for the Federal [...]
Lipitor Trial Day 2: Pfizer v. Ranbaxy
December 3, 2004 INTRODUCTION: Trial Day 2 saw: Ranbaxy’s successful cross-examination of Dr. Roth; Pfizer’s direct examination of Dr. Roger [...]
Lipitor Trial Day 3: Pfizer v Ranbaxy
December 3, 2003 INTRODUCTION Ranbaxy’s cross-examination of Dr. Newton concerning testing; The testimony of Michael Suesserman concerning Lipitor’s commercial success, [...]
Lipitor Trial Day 4: Pfizer v. Ranbaxy
December 6, 2004 INTRODUCTION On Trial Day 4: Ranbaxy completed its cross-examination of Dr. Roush, Pfizer’s expert; Pfizer rested its [...]
Lipitor’s Patent Upheld by Appeals Court
August 7, 2006 Pfizer Inc said today that a panel of the Court of Appeals for the Federal Circuit has [...]
Neurontin 1: Interim Status Report
Introduction. Neurontin, is Pfizer’s (formerly Warner-Lambert’s) $ 2 billion a year FDA-approved epilepsy medication. Warner Lambert’s first generation patents have [...]
Neurontin 2: Generic Competition likely in September ‘02
The battle over Neurontin (whose active ingredient is gabapentin) is heating up: A hearing is scheduled for Monday, September 9, [...]
Norvasc: Federal Circuit will reverse trial & rule for Pfizer
August 31 2003 INTRODUCTION On July 9, 2003, the Federal Circuit Court heard oral argument in Pfizer’s Norvasc© appeal. A [...]
Related Case Type
